Article information
Abstract
Introduction
Infections caused by multiresistant Pseudomonas aeruginosa (MR-PA) have been associated with persistent infections and high mortality in acquired immunodeficiency syndrome (AIDS) patients. Therefore, understanding the predisposing factors for infection/colonization by this agent is critical for controlling outbreaks caused by MR-PA in settings with AIDS patients.
Objective and methodsTo analyze the presence of factors associated with the acquisition of an epidemic MR-PA strain in a hospital with AIDS-predominant admission. A casecontrol study was carried out in which cases and controls were gathered from a prospective cohort of all hospitalized patients in an infectious disease hospital during a five-year study period.
ResultsMultivariate logistic regression analysis demonstrated that enteral nutrition (OR=14.9), parenteral nutrition (OR=10.7), and use of ciprofloxacin (OR=8.9) were associated with a significant and independent risk for MR-PA acquisition.
ConclusionsAlthough cross-colonization was likely responsible for the outbreaks, the use of ciprofloxacin was also an important factor associated with the acquisition of an epidemic MR-PA strain. More studies are necessary to determine whether different types of nutrition could lead to modification of gastrointestinal flora, thereby increasing the risk for infection/colonization by MR-PA in this population.
Keywords:
Pseudomonas aeruginosa
Risk factors
Disease outbreaks
Molecular epidemiology
Acquired immunodeficiency syndrome
Full text is only aviable in PDF
References
[1]
Y. Yakupogullari, B. Otlu, M. Dogukan, et al.
Investigation of a nosocomial outbreak by alginate-producing pan-antibioticresistant Pseudomonas aeruginosa.
Am J Infect Control, 36 (2008), pp. e13-e18
[2]
M.Z.R. Gomes, C.R. Machado, M.S. Conceição, et al.
Outbreaks, persistence, and high mortality rates of multiresistant Pseudomonas aeruginosa infections in a hospital with AIDS-predominant admissions.
Braz J Infect Dis, 15 (2011), pp. 312-322
[3]
M. Thuong, K. Arvaniti, R. Ruimy, et al.
Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit.
J Hosp Infect, 53 (2003), pp. 274-282
[4]
E. Paramythiotou, J.C. Lucet, J.F. Timsit, et al.
Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity.
Clin Infect Dis, 38 (2004), pp. 670-677
[5]
C. Defez, P. Fabbro-Peray, N. Bouziges, et al.
Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection.
J Hosp Infect, 57 (2004), pp. 209-216
[6]
S.A. Nouér, M. Nucci, M.P. de-Oliveira, F.L. Pellegrino, B.M. Moreira.
Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase.
Antimicrob Agents Chemother, 49 (2005), pp. 3663-3667
[7]
C.I. Kang, S.H. Kim, W.B. Park, et al.
Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Microb Drug Resist, 11 (2005), pp. 68-74
[8]
A.P. Zavascki, R.P. Cruz, L.Z. Goldani.
Risk factors for imipenemresistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients.
J Hosp Infect, 59 (2005), pp. 96-101
[9]
A.P. Zavascki, A.L. Barth, P.B. Gaspareto, et al.
Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-⊠-lactamase in two tertiary-care teaching hospitals.
J Antimicrob Chemother, 58 (2006), pp. 882-885
[10]
A. Endimiani, F. Luzzaro, B. Pini, G. Amicosante, G.M. Rossolini, A.Q. Toniolo.
Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.
BMC Infect Dis, 16 (2006), pp. 52
[11]
C.M. Fortaleza, M.P. Freire, C. Filho D de, M. de Carvalho Ramos.
Risk factors for recovery of imipenem- or ceftazidimeresistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil.
Infect Control Hosp Epidemiol, 27 (2006), pp. 901-906
[12]
L.B. Gasink, N.O. Fishman, I. Nachamkin, W.B. Bilker, E. Lautenbach.
Risk factors for and impact of infection or colonization with aztreonam-resistant Pseudomonas aeruginosa.
Infect Control Hosp Epidemiol, 28 (2007), pp. 1175-1180
[13]
S.D. Mentzelopoulos, M. Pratikaki, E. Platsouka, et al.
Prolonged use of carbapenems and colistin predisposes to ventilatorassociated pneumonia by pandrug-resistant Pseudomonas aeruginosa.
Intensive Care Med, 33 (2007), pp. 1524-1532
[14]
B.G. Iversen, T. Jacobsen, H.M. Eriksen, et al.
An outbreak of Pseudomonas aeruginosa infection caused by contaminated mouth swabs.
Clin Infect Dis, 44 (2007), pp. 794-801
[15]
R. Cipriano Souza, A.C. Vicente, V.V. Vieira, et al.
Clindamycin and metronidazole as independent risk factors for nosocomial acquisition of multidrug-resistant Pseudomonas aeruginosa.
J Hosp Infect, 69 (2008), pp. 402-403
[16]
C. Peña, C. Suarez, F. Tubau, et al.
Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrugresistant acquisition in non-critically ill patients.
Eur J Clin Microbiol Infect Dis, 28 (2009), pp. 519-522
[17]
R.C. Cezário, L. Duarte De Morais, J.C. Ferreira, R.M. Costa-Pinto, A.L. da Costa Darini, P.P. Gontijo-Filho.
Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital.
Enferm Infecc Microbiol Clin, 27 (2009), pp. 269-274
[18]
K.J. Eagye, J.L. Kuti, D.P. Nicolau.
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa.
Infect Control Hosp Epidemiol, 30 (2009), pp. 746-752
[19]
J.A. Cortes, S.I. Cuervo, A.M. Urdaneta, et al.
Identifying and controlling a multiresistant Pseudomonas aeruginosa outbreak in a Latin-American cancer centre and its associated risk factors.
Braz J Infect Dis, 13 (2009), pp. 99-103
[20]
A. Kohlenberg, D. Weitzel-Kage, P. van der Linden, et al.
Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.
J Hosp Infect, 74 (2010), pp. 350-357
[21]
J.L. Meynard, F. Barbut, M. Guiguet, et al.
Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients.
J Infect, 38 (1999), pp. 176-181
[22]
F. Vidal, J. Mensa, J.A. Martínez, et al.
Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1.
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 473-477
[23]
F. Sorvillo, G. Beall, P.A. Turner, V.L. Beer, A.A. Kovacs, P.R. Kerndt.
Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure.
Am J Infect Control, 29 (2001), pp. 79-84
[24]
D.L. Paterson.
Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach.
Clin Infect Dis, 34 (2002), pp. 1564-1567
[25]
G. Heinze, M. Schemper.
A solution to the problem of separation in logistic regression.
Stat Med, 21 (2002), pp. 2409-2419
[26]
G.H. Furtado, A.C. Gales, L.B. Perdiz, A.E. Santos, S.B. Wey, E.A. Medeiros.
Risk factors for hospital-acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa in an intensive care unit.
Anaesth Intensive Care, 38 (2010), pp. 994-1001
[27]
E.L. Murphy, B. Wang, R.A. Sacher, et al.
Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection.
Emerg Infect Dis, 10 (2004), pp. 109-116
[28]
S.M. Schneider, P. Le Gall, F. Girard-Pipau, et al.
Total artificial nutrition is associated with major changes in the fecal flora.
Eur J Nutr, 39 (2000), pp. 248-255
[29]
D. Garrel, J. Patenaude, B. Nedelec, et al.
Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial.
Crit Care Med, 31 (2003), pp. 2444-2449
Copyright © 2012. Elsevier Editora Ltda.. All rights reserved
